2. Academic Validation
  3. Novel analgesic peptide derived from Cinobufacini injection suppressing inflammation and pain via ERK1/2/COX-2 pathway

Novel analgesic peptide derived from Cinobufacini injection suppressing inflammation and pain via ERK1/2/COX-2 pathway

  • Int Immunopharmacol. 2024 Nov 15:141:112918. doi: 10.1016/j.intimp.2024.112918.
Li Guo 1,  Sai Zhang 1,  Cong Zhang 1,  Shuang Ren 1,  Zihan Zhou 1,  Fengyuan Wang 1,  Yuexuan Wang 1,  Qiqi Chen 1,  Yubing Wang 1,  Wen-Hui Lee 2,  Kui Zhu 3,  Di Qin 4,  Yuanyuan Gao 5,  Tongyi Sun 6
Affiliations

Affiliations

  • 1 School of Life Science and Technology, Shandong Second Medical University, Weifang 261053, Shandong Province, PR China.
  • 2 Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, PR China.
  • 3 Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Veterinary Medicine, China Agricultural University, Beijing 100193, PR China.
  • 4 School of Life Science and Technology, Shandong Second Medical University, Weifang 261053, Shandong Province, PR China. Electronic address: qindi@sdsmu.edu.cn.
  • 5 School of Pharmacy, Shandong Second Medical University, Weifang 261053, Shandong Province, PR China. Electronic address: yyg20062006@126.com.
  • 6 School of Life Science and Technology, Shandong Second Medical University, Weifang 261053, Shandong Province, PR China. Electronic address: tysun@sdsmu.edu.cn.
PMID: 39159558 DOI: 10.1016/j.intimp.2024.112918
Abstract

Inflammatory pain is a chronic pain caused by peripheral tissue inflammation, seriously impacting the patient's life quality. Cinobufacini injection, as a traditional Chinese medicine injection preparation, shows excellent efficacy in anti-inflammatory and analgesic treatment in patients with advanced tumors. In this study, a novel analgesic peptide CI5 with anti-inflammatory and analgesic bio-functions that naturally presents in Cinobufacini injection and its regulatory mechanism are reported. Our results showed that the administration of CI5 significantly relieved the pain of mice in the acetic acid twisting analgesic model and formalin inflammatory pain model. Furthermore, CI5 effectively reduced the inflammatory cytokines (IL-6, TNF-α and IL-1β) and inflammatory mediator (PGE2) expressions, and prevented the carrageenan-induced paw edema in mice. Further LC-MS/MS results showed the anti-inflammatory and analgesic bio-functions of CI5 depended on its interaction with the Rac-2 protein upstream of ERK1/2 and the inflammatory signaling pathway (ERK1/2/COX-2 axis). In summary, CI5, as a novel natural candidate identified from Cinobufacini injection, showed substantial clinical promise for inflammatory pain treatments.

Keywords

Analgesia; Analgesic peptides; Anti-inflammation; Cinobufacini injection; ERK1/2/COX-2 pathway.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P5985
    98.03%, ERK1/2 Activator
    ERK